Ligand Pharmaceuticals (LGND)
(Real Time Quote from BATS)
$104.50 USD
-4.49 (-4.12%)
Updated Aug 1, 2024 03:10 PM ET
NA Value
NA Growth NA Momentum NA VGMLigand Pharmaceuticals (LGND) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$127.25 | $144.00 | $95.00 | 16.75% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Ligand Pharmaceuticals comes to $127.25. The forecasts range from a low of $95.00 to a high of $144.00. The average price target represents an increase of 16.75% from the last closing price of $108.99.
Analyst Price Targets (4 )
Broker Rating
Ligand Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 20% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LGND.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 3 | 3 |
Buy | 1 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/30/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
7/9/2024 | Craig-Hallum | Matthew G Hewitt | Not Available | Strong Buy |
6/27/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
4/12/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
1/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $127.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 87 of 252 |
Current Quarter EPS Est: | 1.10 |